John Evans Professor of Chemistry and Professor of Molecular Biosciences; Weinberg College of Arts and Sciences; Member, Interdepartmental Neuroscience Program; Member, Center for Molecular Innovation and Drug Discovery; Member, Interdepartmental Biological Sciences Program; Member, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Dr. Silverman was awarded the 2009 Perkin Medal for his "outstanding work in applied chemistry," and he was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame in 2009. Most of his research is in the area of neurodegenerative diseases, such as Parkinson's disease, cerebral palsy, and amyotrophic lateral sclerosis, and in epilepsy, addiction, and antibacterial agents, particularly with regard to the design of medicinal agents and mechanisms of drug action. In 1989 Dr. Silverman’s group first synthesized an organic molecule, that ultimately was marketed as LyricaTM, a drug currently used to combat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder, marketed by Pfizer, Inc. His philanthropic donation helped fund the Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics.
Office: Silverman Hall 4603
r-silverman [at] northwestern [dot] edu
Office: Silverman Hall 4601
pamela-beck [at] northwestern [dot] edu